This is a summary of the European public assessment report (EPAR) for Valtropin. It explains how the
Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recomm ndations on the conditions of use for Valtropin.
- Somatropin biopartners - somatropin
Popisanih lijekova na recept. Tvar: "Somatropin"
Valtropin is a ‘biosimilar’ medicine. This means that Valtropin is similar to a biological medicine (the
‘reference medicine’) that is already authorised in the European Union (EU) and that Valtropin and the
- Somatropin biopartners - BioPartners GmbH
Popisanih lijekova na recept. Proizvođač: "BioPartners GmbH"
reference medicine contain the same active substance. The reference medicine for Valtropin is Medicinal
Humatrope. For more inform tion on biosimilar medicines, see the
- Somatropin biopartners - H01AC01
Popisanih lijekova na recept. ATK šifra: "H01AC01"
What is Valtropin used for?
Valtropin is used to treat children in the following situations:
children from two years of age and adolescents who fail to grow because they lack growth hormone (replacement therapy);